How to Help Your Patients Find Ingrezza in Stock: A Provider's Guide

Helping patients access Ingrezza (valbenazine) requires navigating a multi-step process that goes beyond writing a prescription. As the prescriber, your office is the critical link between the patient, the insurance company, and the specialty pharmacy. This guide walks through everything your practice needs to successfully get Ingrezza into your patients' hands.

Step 1: Use the INGREZZA Treatment Form — Not a Standard E-Rx

The single most important step your office can take: use the INGREZZA Treatment Form provided by Neurocrine Biosciences rather than routing a standard electronic prescription. Here's why this matters:

The Treatment Form simultaneously serves as a prescription AND enrolls the patient in Neurocrine Access Support.

It routes directly to a network specialty pharmacy — bypassing the retail pharmacy rejection.

It triggers automatic enrollment in the copay savings card and patient assistance program eligibility check.

Download the form at ingrezzahcp.com or by calling Neurocrine Access Support at 1-844-647-3992. Once completed, fax or submit via the Neurocrine portal. A Regional Patient Access Manager (RPAM) will follow up within 1–2 business days.

Step 2: Build Your Prior Authorization Documentation

Prior authorization is required by essentially all payers. To maximize PA approval speed, prepare the following before submitting:

For Tardive Dyskinesia: Document the primary psychiatric diagnosis, list of antipsychotic/metoclopramide exposures with approximate duration, and AIMS (Abnormal Involuntary Movement Scale) score or detailed clinical description of involuntary movements.

For HD Chorea: Document the genetically confirmed Huntington's disease diagnosis and Total Maximal Chorea (TMC) score or UHDRS-based assessment.

Step therapy: If your plan requires prior failure of another VMAT2 inhibitor (Austedo), document any prior trial, reason for discontinuation, or medical rationale for starting with Ingrezza (e.g., once-daily without food requirement, tolerability).

Step 3: Understand Financial Assistance Options to Reduce Patient Burden

Ingrezza's retail cost exceeds $7,900 per month — but most patients with commercial insurance pay $10 or less per month with the INBRACE Savings Card. Understanding which program fits your patient's situation will prevent cost-related non-adherence:

Commercial insurance: INBRACE Savings Card (copay as low as $0/month). Automatically applied through the Treatment Form enrollment. Not valid for government-funded insurance.

Uninsured or underinsured: Patient Assistance Program provides Ingrezza at no cost to qualifying patients. Call 1-844-647-3992 to apply.

Medicare: Approximately 46% of Medicare Part D plans cover Ingrezza. Copay savings card is not valid for Medicare patients. Low-income patients may qualify for Extra Help (LIS) through Medicare Part D.

New patients (any insurance): INGREZZA Start Program offers a free 30-day supply while insurance is being processed. Enroll by downloading the form from ingrezza.neurocrineaccesssupport.com.

Step 4: Know Which Pharmacies Can Fill Ingrezza

Ingrezza is available through Neurocrine's network of specialty and local affiliated pharmacies. When the Treatment Form is submitted, the specialty pharmacy will contact the patient within 1–3 business days to arrange dispensing and delivery. Common specialty pharmacies in the network include Accredo, CVS Specialty, and Walgreens Specialty — but local affiliated pharmacies also exist.

For patients who need to find a local pharmacy that can fill Ingrezza, recommend medfinder — a service that calls pharmacies on the patient's behalf to locate one that can fill their specific prescription. This saves both patient and staff significant time.

Step 5: Managing Ongoing Access — Refills and Renewals

PA renewals are required annually by most payers. Build a reminder system in your EHR to flag Ingrezza patients for PA renewal 30–60 days before current authorization expires. Most payers require reauthorization documentation showing continued clinical benefit (e.g., maintained reduction in AIMS score or TMC score, or documented clinical stability).

Neurocrine's RPAMs can also proactively assist with renewal submissions — contact your local RPAM or call 1-844-647-3992.

Quick Reference: Key Contacts for Ingrezza Access

Neurocrine Access Support: 1-844-647-3992, Mon–Fri 8 am–8 pm ET

HCP Resources: ingrezzahcp.com — Treatment Form, PA tools, samples

Patient medfinder: medfinder.com — pharmacy locator service for patients who can't find a fill location

Also read: Ingrezza shortage: What providers need to know in 2026.